Sarcopenia, defined by the European Working Group on Sarcopenia in Older People (EWGSOP2, 2019) as a progressive, generalised skeletal muscle disorder associated with adverse outcomes including falls, functional decline, frailty and death, is the central biological substrate of the frailty syndrome. Its aetiology is multifactorial, arising from interplay between neurological, endocrine, immunological and metabolic dysregulation accumulating across the lifecourse.
Ageing muscle undergoes progressive denervation of fast-twitch type II motor units that are not adequately reinnervated. The result is reduced muscle fibre cross-sectional area, preferential atrophy of glycolytic fast-twitch fibres and relative preservation of slow-twitch oxidative type I fibres. This shift impairs the capacity to generate rapid, powerful contractions – the physiological basis for slow gait speed and difficulty rising from a chair, both cardinal frailty features.
Testosterone, insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone (DHEA) all fall progressively from the fifth decade. Reduced IGF-1 signalling through the phosphoinositide 3-kinase (PI3K)–Akt–mTOR pathway diminishes protein synthesis and satellite cell activation, impairing muscle repair and hypertrophy. Growth hormone secretion also declines, reducing hepatic IGF-1 production through the somatotrophic axis.
A chronic low-grade inflammatory state, termed “inflammaging”, further drives sarcopenic muscle loss. Elevated interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α) and C-reactive protein activate the nuclear factor kappa-B (NF-κB) pathway within myocytes, upregulating the ubiquitin-proteasome degradation system and promoting net protein catabolism. This is perpetuated by adipose-derived cytokines, falling oestrogen (which has anti-inflammatory properties) and impaired mitochondrial function with attendant reactive oxygen species (ROS).
Ageing mitochondria accumulate somatic mutations in mitochondrial DNA, show reduced oxidative phosphorylation efficiency and produce excess ROS. Impaired mitophagy allows damaged organelles to accumulate. The resulting energy deficit impairs protein synthesis, reduces satellite cell function and promotes apoptosis of myonuclei, accelerating loss of muscle mass and function.
Inadequate dietary protein, particularly during catabolic illness, compounds the age-related fall in muscle protein synthesis. The recommended protein intake for older adults at risk of sarcopenia is 1.0–1.2 g/kg/day at minimum (ESPEN), rising to 1.2–1.5 g/kg/day during acute illness. Vitamin D deficiency, highly prevalent in older UK adults, independently impairs muscle function through vitamin D receptor (VDR)-mediated transcription of genes encoding contractile proteins.
Fried and colleagues (2001) operationalised frailty as a distinct clinical syndrome defined by five measurable features: unintentional weight loss (>4.5 kg or >5% of body weight in the preceding year), self-reported exhaustion (from Centre for Epidemiological Studies Depression Scale items), weak grip strength (below sex- and BMI-stratified thresholds), slow walking speed (below sex- and height-stratified thresholds over 4.57 metres) and low physical activity (below the lowest quintile of weekly kilocalorie expenditure). Three or more criteria define frailty; one or two define a pre-frailty state associated with significant risk of progression; zero defines robustness.
The phenotype has been validated across multiple prospective cohorts as an independent predictor of hospitalisation, disability, institutionalisation and death, even after adjustment for age, comorbidity and cognitive status. Its criteria map onto discrete biological pathways: weight loss reflects negative energy balance from inflammaging and anorexia of ageing; exhaustion reflects mitochondrial insufficiency and anaemia; weakness and slowness reflect sarcopenia; and low activity both reflects and perpetuates the syndrome in a self-reinforcing cycle.
The phenotype model is most applicable in community and outpatient settings, where time allows formal measurement of walking speed and grip strength. In the acute hospital its operationalisation is often impractical, and the Clinical Frailty Scale offers a validated, efficient alternative.
The Clinical Frailty Scale (CFS), developed by Rockwood and colleagues in the Canadian Study of Health and Aging, is a nine-point ordinal scale characterising frailty from clinical judgement about a patient's mobility, energy, physical activity and function in the two weeks before an acute illness. Scores range from 1 (Very Fit) to 9 (Terminally Ill). Scores of 5 (Mildly Frail) to 6 (Moderately Frail) identify people who clearly depend on others for higher-order activities of daily living; scores of 7 (Severely Frail) and above indicate dependence for personal care or complete dependence.
The CFS is extensively validated in acute settings and endorsed by NHS England, NICE and the British Geriatrics Society. It predicts inpatient mortality, discharge destination, prolonged length of stay and 30-day readmission. Its applicability in critical-care framing was widely debated during the COVID-19 pandemic; it must reflect premorbid status rather than the condition at assessment, and must not be applied to patients with stable disability (for example stable paraplegia or stable cerebral palsy), where scores would misleadingly classify non-progressive impairment as frailty.
The cumulative deficit model, also developed by Rockwood, conceptualises frailty as the accumulation of deficits across health domains: symptoms, signs, diagnoses, laboratory abnormalities and functional impairments. The Frailty Index is the ratio of deficits present to deficits considered, expressed as a proportion; a Frailty Index above 0.25 indicates frailty. It has superior predictive validity for mortality at population level and can be derived from routinely collected data, making it valuable for research and epidemiology, though less practical at the bedside.
| Feature | Frailty phenotype (Fried) | Cumulative deficit (Frailty Index) |
|---|---|---|
| Concept | Frailty as a discrete clinical syndrome | Frailty as accumulation of health deficits |
| Measurement | Five criteria (WEAKS), formally measured | Ratio of deficits present to deficits considered |
| Threshold | 3 or more = frail; 1–2 = pre-frail | Frailty Index >0.25 = frail |
| Best setting | Community and outpatient | Research and population, from routine data or the electronic health record |
| Strength | Identifies a discrete, physiologically grounded syndrome | Superior population-level prediction of mortality |
Both models measure frailty but through different conceptual lenses, and they do not always agree at the individual level.
No pharmacological agent has been shown to reverse frailty. The most robust evidence supports structured, progressive resistance exercise as the cornerstone intervention. Resistance training at moderate-to-high intensity (70–85% of one-repetition maximum), performed two to three times weekly, increases muscle mass, strength and physical performance in frail older adults. The SPRINTT trial (2019) showed that physical activity combined with dietary protein supplementation reduced mobility disability in community-dwelling frail and pre-frail older adults.
Nutritional optimisation is an essential adjunct: dietitian assessment, correction of protein-energy malnutrition, vitamin D supplementation (800 IU daily in those at risk, per NICE PH56) and management of the anorexia of ageing. Oral nutritional supplements may be warranted where dietary modification alone is insufficient, guided by MUST (Malnutrition Universal Screening Tool) scoring. Comprehensive geriatric assessment (CGA), covered in Topic 2, provides the systematic framework within which frailty interventions are delivered, and has the strongest evidence for improving outcomes in frail older adults admitted to hospital.
Comprehensive geriatric assessment is a multidimensional, interdisciplinary diagnostic process that determines the medical, psychological, functional and social capabilities and limitations of an older frail person, with the aim of developing an integrated plan for treatment and long-term follow-up. It is not simply a clinical assessment: it is a coordinated, goal-directed process in which the multidisciplinary team aggregates data across domains to generate an individualised care plan addressing the totality of the patient's needs rather than isolated disease episodes.
Its theoretical basis is the recognition that frailty and multimorbidity produce interdependent problems: functional impairment may worsen cognition, polypharmacy may precipitate delirium, and social isolation may impede recovery from acute illness. A single-organ approach is therefore insufficient; CGA provides the structure for holistic evaluation and for coordinating interventions across multiple domains at once.
CGA is organised around seven domains, each with validated assessment tools. In older frail patients the most important clinical issue may not be the presenting complaint, so a complete problem list across all domains is essential.
| Domain | What it assesses | Validated tools |
|---|---|---|
| Medical | History, examination, diagnoses, investigations, medication burden, complete problem list | Structured medication review (Topics 14–15) |
| Functional | Basic ADLs (bathing, dressing, toileting, transferring, continence, feeding) and instrumental ADLs (shopping, cooking, finances, medication, transport) | Katz Index, Lawton–Brody Scale, Barthel Index (0–100) |
| Cognitive | Delirium and cognitive impairment screening and profiling | AMTS (10 items; <8 warrants further assessment), MoCA (30), ACE-III (100) |
| Psychological | Mood, particularly depression (often underdiagnosed) and anxiety | GDS-15, PHQ-9 |
| Social | Living situation, informal carer support, networks, finances, housing, carer breakdown risk | Carer assessment under the Care Act 2014 |
| Environmental | Home safety and accessibility; hazards; access to essential facilities | Occupational therapy home assessment |
| Nutritional | Malnutrition risk (associated with longer stay, complications, mortality) | MUST, Mini Nutritional Assessment (MNA) |
The landmark Cochrane meta-analysis by Ellis and colleagues (2017, updated), encompassing more than 16 randomised controlled trials, showed that CGA delivered on a dedicated geriatric ward (ward-based CGA) significantly improved rates of living at home at 6–12 months and reduced death or institutionalisation compared with standard acute care. The number needed to treat for one additional patient living at home was approximately 33. Ward-based CGA was consistently superior to CGA consultation models, in which a geriatric team advises on a non-geriatric ward; the consultation model showed no significant benefit in the meta-analysis.
In community settings, CGA delivered through specialised community geriatric services (intermediate care, reablement, community multidisciplinary teams) reduces care home admissions and supports independence. Frailty units, ambulatory care pathways and frailty surgery liaison services extend CGA principles to the peri-operative, emergency and outpatient domains. NICE NG56 (Multimorbidity, 2016) recommends that patients with multimorbidity receive care that is coordinated, individualised and minimises treatment burden.
Multimorbidity, the presence of two or more long-term conditions, affects over 50% of those aged over 75 in the UK and is the default state of patients seen by geriatricians. Its complexity arises not only from coexisting conditions but from their interactions, the cumulative burden of treatment and competing priorities between disease-specific guidelines. NICE NG56 cautions against the uncritical application of single-disease guidelines in multimorbidity, where adherence to each guideline simultaneously may cause inappropriate polypharmacy, quality-of-life impairment and unsafe drug combinations.
Within CGA, multimorbidity is managed through an iterative process of problem prioritisation, shared decision-making about treatment goals (the relative importance of life extension, symptom control and maintenance of function), medication review (Topics 14–15) and advance care planning (Topics 20–21). Goal concordance, ensuring the plan reflects the patient's own priorities, is both ethically required under the Mental Capacity Act 2005 and clinically associated with improved adherence and outcomes.
About one-third of community-dwelling adults over 65, and half of those over 80, fall each year. Falls are the leading cause of injury-related hospitalisation and death in older adults in the UK, with hip fracture the most devastating consequence. Beyond injury, falls produce a cycle of fear, reduced activity, deconditioning and further falls – the post-fall syndrome. The direct cost to the NHS exceeds £2 billion annually.
These include impaired balance and gait (vestibular dysfunction, cerebellar disease, peripheral neuropathy), lower-limb muscle weakness (sarcopenia), visual impairment (reduced acuity, contrast sensitivity and depth perception), cognitive impairment (particularly executive dysfunction impairing hazard avoidance) and postural hypotension. Contributing comorbidities include Parkinson's disease (rigidity, festinating gait, impaired postural reflexes), stroke, vitamin D deficiency and uncontrolled diabetes causing hypoglycaemia or peripheral neuropathy.
Polypharmacy is a critical modifiable risk factor. Fall-associated medications include psychotropics (benzodiazepines, antipsychotics, antidepressants, which impair reaction time and balance), antihypertensives (postural hypotension), opioids and hypoglycaemic agents. The STOPP (Screening Tool of Older Persons' Prescriptions) criteria identify medications inappropriately prescribed in older adults at risk of falls, and NICE NG249 (2025) makes medication review a mandatory component of any falls assessment.
Environmental hazards interact with intrinsic vulnerability to precipitate a fall: loose floor coverings, poor lighting, absence of grab rails in bathrooms and on stairs, ill-fitting footwear and external hazards such as uneven pavements. Occupational therapy home assessment is an evidence-based intervention for identifying and remediating these hazards, with the strongest evidence in people with a history of falls.
Postural hypotension is a sustained fall in systolic blood pressure of at least 20 mmHg, or diastolic of at least 10 mmHg, within three minutes of standing from supine or seated. It affects around 20% of community-dwelling older adults and up to 50% of nursing home residents, and is an independent risk factor for falls, syncope and cardiovascular events.
On standing, gravitational pooling of 500–1000 mL of blood in the splanchnic and lower-limb venous system reduces cardiac preload and blood pressure. In healthy individuals, carotid sinus and aortic arch baroreceptors trigger reflex tachycardia and peripheral vasoconstriction to restore pressure within 30 seconds. In older adults this reflex is attenuated by reduced baroreceptor sensitivity and impaired autonomic function.
Causes are neurogenic (autonomic failure, idiopathic, Parkinson's disease, multiple system atrophy, diabetes) and non-neurogenic (volume depletion from dehydration, blood loss or diuretics; cardiac pump failure; vasodilatory medications including ACE inhibitors, alpha-blockers and nitrates). Iatrogenic causes are the most common and important modifiable factor, with antihypertensives, diuretics, tricyclic antidepressants, alpha-blockers (for benign prostatic hypertrophy) and antiparkinsonian agents all implicated.
Assessment requires lying and standing blood pressure, ideally with one- and three-minute readings (the Active Stand test). Investigations include electrolytes and renal function (volume status), full blood count (anaemia), lying and standing heart rate (neurogenic postural hypotension typically shows an inadequate heart rate rise), ECG, and echocardiography where a cardiac cause is suspected.
Management includes medication review and reduction, adequate hydration, compression hosiery, head-of-bed elevation, small frequent meals (to reduce post-prandial hypotension) and physical countermanoeuvres. Where non-pharmacological measures are insufficient, fludrocortisone (a mineralocorticoid) or midodrine (an alpha-1 adrenoceptor agonist) may be considered.
NICE NG249 (2025) recommends that older adults presenting after a fall, or identified as at risk, are asked about falls in the past 12 months and offered a multifactorial assessment where indicated, covering gait, balance and mobility (for example the Timed Up and Go test and the Berg Balance Scale). The Timed Up and Go test measures the time to rise from a chair, walk 3 metres, turn, walk back and sit. NICE NG249 recommends against using timed test cut-offs or falls risk-prediction tools to predict future falls; the Timed Up and Go informs functional assessment and intervention planning rather than risk stratification.
Interventions proven to reduce falls and fall-related injuries include supervised strength and balance exercise programmes (OTAGO, FaME – Falls Management Exercise), home hazard modification, gradual withdrawal of psychotropic medication, antihypertensive dose reduction where clinically appropriate, vitamin D supplementation (800 IU/day in those at risk, per NICE PH56) and, for those at fracture risk, bone protection therapy. Multifactorial interventions are more effective than single-component interventions (Cochrane 2019, Sherrington et al.).
Falls assessment must integrate fracture risk assessment. The FRAX tool (WHO), using clinical risk factors and optionally femoral neck bone mineral density from DXA, calculates the 10-year probability of a major osteoporotic fracture (hip, spine, wrist, humerus) and of hip fracture specifically. In the UK, FRAX is interpreted against the NOGG (National Osteoporosis Guideline Group) thresholds, which stratify patients into treatment, assessment (DXA required before decision) and reassurance categories.
DXA measures bone mineral density at the lumbar spine and femoral neck, expressed as a T-score (standard deviations from mean young adult density) and Z-score (standard deviations from an age-matched mean). A fragility fracture – a fracture from a force equivalent to a fall from standing height or less – is a clinical diagnosis of osteoporosis regardless of T-score and should trigger bone protection therapy.
| Category | T-score (WHO) | Note |
|---|---|---|
| Normal | -1.0 or above | Measured at lumbar spine or femoral neck |
| Osteopenia | -1.0 to -2.5 | Reduced density, below the osteoporosis threshold |
| Osteoporosis | -2.5 or below | Also diagnosed clinically by any fragility fracture, whatever the T-score |
First-line pharmacological bone protection in postmenopausal women and men over 50 with osteoporosis or a fragility fracture is an oral bisphosphonate: alendronic acid 70 mg weekly (NICE TA464). Calcium and vitamin D (calcium carbonate 1200 mg daily, vitamin D 800 IU daily) should be co-prescribed unless dietary intake is sufficient.
| Drug | Class and mechanism | Route, line and notes |
|---|---|---|
| Alendronic acid 70 mg weekly | Nitrogen-containing bisphosphonate; inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, impairing osteoclast function | Oral, first-line (NICE TA464). Reduces vertebral fracture risk ~45% and hip fracture ~51% (FIT trial) |
| Zoledronic acid 5 mg | Bisphosphonate (as above) | IV annually; for oesophageal dysmotility or inability to remain upright (NICE TA464) |
| Denosumab 60 mg | Monoclonal antibody targeting RANK-L; inhibits osteoclast differentiation and function | Subcutaneous every 6 months (NICE TA204). Do not stop without transitioning to a bisphosphonate (rebound fracture risk) |
| Romosozumab | Sclerostin inhibitor; dual anabolic and anti-resorptive action | For severe osteoporosis or bisphosphonate failure (NICE guidance) |
| Teriparatide | Recombinant parathyroid hormone 1-34; anabolic, stimulates osteoblasts | For severe osteoporosis with multiple fractures or bisphosphonate failure |
Multimorbidity is the presence of two or more long-term physical or mental health conditions in one individual simultaneously. It is distinct from comorbidity, which implies a primary index condition with additional conditions viewed as secondary. Multimorbidity is the norm rather than the exception in older adults: by age 65, more than half the UK population has at least two long-term conditions, rising to over 70% by age 75. Prevalence is disproportionately high in areas of socioeconomic deprivation, occurring on average 10–15 years earlier in deprived populations.
Clinical complexity in multimorbidity arises from several interrelated sources:
Treatment burden is the total workload imposed on a patient by their healthcare: medication administration and monitoring, attendance at multiple appointments across specialties, lifestyle modifications, dietary restrictions and self-monitoring tasks such as blood glucose or blood pressure recording. In multimorbidity this burden can become overwhelming, leading to reduced adherence, reduced engagement with services and paradoxical worsening of outcomes. Patients with high treatment burden describe healthcare as a second job. Tran and colleagues (2012) conceptualised treatment burden as a construct distinct from disease burden, influenced by healthcare system organisation, patient health literacy and social support.
NICE NG56 (2016) sets out specific guidance for managing patients with multiple long-term conditions. Key principles include: taking a patient-centred approach to identify priorities, preferences and concerns; discussing the benefits and harms of individual treatments in the context of all conditions; considering reducing or stopping medications that cause harm or offer limited benefit in the context of multimorbidity; and ensuring care is coordinated across primary and secondary care. NICE NG56 explicitly recommends against applying single-condition guidelines without considering their combined impact.
Shared decision-making is central. Using validated tools such as the Option Grid or structured consultation frameworks, clinicians should explore treatment preferences, priorities among competing outcomes (for example prioritising symptom management over mortality reduction) and tolerance for treatment burden. This process is ethically grounded in autonomy and beneficence and is pragmatically associated with improved adherence, as patients who contribute to decisions are more likely to sustain agreed interventions.